MiR-196a ameliorates phenotypes of huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models

Pei Hsun Cheng, Chia Ling Li, Yu Fan Chang, Shaw-Jenq Tsai, Yen Yu Lai, Anthony W.S. Chan, Chuan Mu Chen, Shang-Hsun Yang

研究成果: Article

49 引文 (Scopus)

摘要

Huntington disease (HD) is a dominantly inherited neurodegenerative disorder characterized by dysregulation of various genes. Recently, microRNAs (miRNAs) have been reported to be involved in this dysregulation, suggesting that manipulation of appropriate miRNA regulation may have a therapeutic benefit. Here, we report the beneficial effects of miR-196a (miR196a) on HD in cell, transgenic mouse models, and human induced pluripotent stem cells derived from one individual with HD (HD-iPSCs). In the in vitro results, a reduction of mutant HTT and pathological aggregates, accompanying the overexpression of miR-196a, was observed in HD models of human embryonic kidney cells and mouse neuroblastoma cells. In the in vivo model, HD transgenic mice overexpressing miR-196a revealed the suppression of mutant HTT in the brain and also showed improvements in neuropathological progression, such as decreases of nuclear, intranuclear, and neuropil aggregates and late-stage behavioral phenotypes. Most importantly, miR-196a also decreased HTT expression and pathological aggregates when HD-iPSCs were differentiated into the neuronal stage. Mechanisms of miR-196a in HD might be through the alteration of ubiquitin-proteasome systems, gliosis, cAMP response element-binding protein pathway, and several neuronal regulatory pathways in vivo. Taken together, these results show that manipulating miR-196a provides beneficial effects in HD, suggesting the potential therapeutical role of miR-196a in HD.

原文English
頁(從 - 到)306-312
頁數7
期刊American Journal of Human Genetics
93
發行號2
DOIs
出版狀態Published - 2013 八月 8

指紋

Induced Pluripotent Stem Cells
Huntington Disease
Transgenic Mice
Phenotype
MicroRNAs
Cyclic AMP Response Element-Binding Protein
Gliosis
Neuropil
Proteasome Endopeptidase Complex
Ubiquitin
Neuroblastoma
Neurodegenerative Diseases
Kidney

All Science Journal Classification (ASJC) codes

  • Genetics
  • Genetics(clinical)

引用此文

Cheng, Pei Hsun ; Li, Chia Ling ; Chang, Yu Fan ; Tsai, Shaw-Jenq ; Lai, Yen Yu ; Chan, Anthony W.S. ; Chen, Chuan Mu ; Yang, Shang-Hsun. / MiR-196a ameliorates phenotypes of huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models. 於: American Journal of Human Genetics. 2013 ; 卷 93, 編號 2. 頁 306-312.
@article{e80a0bed84d54dc8b05dc859698339a7,
title = "MiR-196a ameliorates phenotypes of huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models",
abstract = "Huntington disease (HD) is a dominantly inherited neurodegenerative disorder characterized by dysregulation of various genes. Recently, microRNAs (miRNAs) have been reported to be involved in this dysregulation, suggesting that manipulation of appropriate miRNA regulation may have a therapeutic benefit. Here, we report the beneficial effects of miR-196a (miR196a) on HD in cell, transgenic mouse models, and human induced pluripotent stem cells derived from one individual with HD (HD-iPSCs). In the in vitro results, a reduction of mutant HTT and pathological aggregates, accompanying the overexpression of miR-196a, was observed in HD models of human embryonic kidney cells and mouse neuroblastoma cells. In the in vivo model, HD transgenic mice overexpressing miR-196a revealed the suppression of mutant HTT in the brain and also showed improvements in neuropathological progression, such as decreases of nuclear, intranuclear, and neuropil aggregates and late-stage behavioral phenotypes. Most importantly, miR-196a also decreased HTT expression and pathological aggregates when HD-iPSCs were differentiated into the neuronal stage. Mechanisms of miR-196a in HD might be through the alteration of ubiquitin-proteasome systems, gliosis, cAMP response element-binding protein pathway, and several neuronal regulatory pathways in vivo. Taken together, these results show that manipulating miR-196a provides beneficial effects in HD, suggesting the potential therapeutical role of miR-196a in HD.",
author = "Cheng, {Pei Hsun} and Li, {Chia Ling} and Chang, {Yu Fan} and Shaw-Jenq Tsai and Lai, {Yen Yu} and Chan, {Anthony W.S.} and Chen, {Chuan Mu} and Shang-Hsun Yang",
year = "2013",
month = "8",
day = "8",
doi = "10.1016/j.ajhg.2013.05.025",
language = "English",
volume = "93",
pages = "306--312",
journal = "American Journal of Human Genetics",
issn = "0002-9297",
publisher = "Cell Press",
number = "2",

}

MiR-196a ameliorates phenotypes of huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models. / Cheng, Pei Hsun; Li, Chia Ling; Chang, Yu Fan; Tsai, Shaw-Jenq; Lai, Yen Yu; Chan, Anthony W.S.; Chen, Chuan Mu; Yang, Shang-Hsun.

於: American Journal of Human Genetics, 卷 93, 編號 2, 08.08.2013, p. 306-312.

研究成果: Article

TY - JOUR

T1 - MiR-196a ameliorates phenotypes of huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models

AU - Cheng, Pei Hsun

AU - Li, Chia Ling

AU - Chang, Yu Fan

AU - Tsai, Shaw-Jenq

AU - Lai, Yen Yu

AU - Chan, Anthony W.S.

AU - Chen, Chuan Mu

AU - Yang, Shang-Hsun

PY - 2013/8/8

Y1 - 2013/8/8

N2 - Huntington disease (HD) is a dominantly inherited neurodegenerative disorder characterized by dysregulation of various genes. Recently, microRNAs (miRNAs) have been reported to be involved in this dysregulation, suggesting that manipulation of appropriate miRNA regulation may have a therapeutic benefit. Here, we report the beneficial effects of miR-196a (miR196a) on HD in cell, transgenic mouse models, and human induced pluripotent stem cells derived from one individual with HD (HD-iPSCs). In the in vitro results, a reduction of mutant HTT and pathological aggregates, accompanying the overexpression of miR-196a, was observed in HD models of human embryonic kidney cells and mouse neuroblastoma cells. In the in vivo model, HD transgenic mice overexpressing miR-196a revealed the suppression of mutant HTT in the brain and also showed improvements in neuropathological progression, such as decreases of nuclear, intranuclear, and neuropil aggregates and late-stage behavioral phenotypes. Most importantly, miR-196a also decreased HTT expression and pathological aggregates when HD-iPSCs were differentiated into the neuronal stage. Mechanisms of miR-196a in HD might be through the alteration of ubiquitin-proteasome systems, gliosis, cAMP response element-binding protein pathway, and several neuronal regulatory pathways in vivo. Taken together, these results show that manipulating miR-196a provides beneficial effects in HD, suggesting the potential therapeutical role of miR-196a in HD.

AB - Huntington disease (HD) is a dominantly inherited neurodegenerative disorder characterized by dysregulation of various genes. Recently, microRNAs (miRNAs) have been reported to be involved in this dysregulation, suggesting that manipulation of appropriate miRNA regulation may have a therapeutic benefit. Here, we report the beneficial effects of miR-196a (miR196a) on HD in cell, transgenic mouse models, and human induced pluripotent stem cells derived from one individual with HD (HD-iPSCs). In the in vitro results, a reduction of mutant HTT and pathological aggregates, accompanying the overexpression of miR-196a, was observed in HD models of human embryonic kidney cells and mouse neuroblastoma cells. In the in vivo model, HD transgenic mice overexpressing miR-196a revealed the suppression of mutant HTT in the brain and also showed improvements in neuropathological progression, such as decreases of nuclear, intranuclear, and neuropil aggregates and late-stage behavioral phenotypes. Most importantly, miR-196a also decreased HTT expression and pathological aggregates when HD-iPSCs were differentiated into the neuronal stage. Mechanisms of miR-196a in HD might be through the alteration of ubiquitin-proteasome systems, gliosis, cAMP response element-binding protein pathway, and several neuronal regulatory pathways in vivo. Taken together, these results show that manipulating miR-196a provides beneficial effects in HD, suggesting the potential therapeutical role of miR-196a in HD.

UR - http://www.scopus.com/inward/record.url?scp=84881668179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881668179&partnerID=8YFLogxK

U2 - 10.1016/j.ajhg.2013.05.025

DO - 10.1016/j.ajhg.2013.05.025

M3 - Article

C2 - 23810380

AN - SCOPUS:84881668179

VL - 93

SP - 306

EP - 312

JO - American Journal of Human Genetics

JF - American Journal of Human Genetics

SN - 0002-9297

IS - 2

ER -